Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Tempus AI Cl A (TEM)

Tempus AI Cl A (TEM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Tempus Highlights Landmark Publication Demonstrating Safe, Real-World Deployment of Paige Prostate AI Suite in the UK National Health Service Business Wire - Thu Jul 16, 7:30AM CDT

Findings from the multi-center Articulate Pro study show Paige Prostate improves diagnostic consistency, accelerates turnaround times, and reduces laboratory workloads

TEM : 53.59 (-6.39%)
Tempus to Report Second Quarter 2026 Financial Results on July 30 Business Wire - Thu Jul 9, 8:00AM CDT

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it will report financial results for the second quarter ended June 30, 2026,...

TEM : 53.59 (-6.39%)
Solventum Corp- healthcare phone-by ipopba via iStock
Tempus AI Stock Faces a Make-or-Break Moment After Its Recent Pullback Barchart - Mon Jun 29, 9:36AM CDT

Tempus AI's stock has hit a rough patch, but fundamentals remain solid. What does it mean for investors?

ARKG : 40.09 (-2.74%)
AZN : 169.29 (+0.55%)
MRK : 127.63 (+3.25%)
GILD : 136.30 (+3.49%)
TEM : 53.59 (-6.39%)
GSK : 52.77 (+2.57%)
ARKK : 76.67 (-3.68%)
BMY : 60.51 (+3.05%)
Tempus Announces Research Collaboration with Angiosarcoma Awareness, Inc. to Uncover Insights on Rare Cancers Business Wire - Thu Jun 25, 7:30AM CDT

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a research collaboration with Angiosarcoma Awareness, Inc....

TEM : 53.59 (-6.39%)
Tempus Announces Multi-Center Validation of AI-Enabled ECG Model for Predicting Atrial Fibrillation Risk Published in Heart Rhythm Business Wire - Thu Jun 11, 7:30AM CDT

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced publication of successful multi-site validation of its software ...

TEM : 53.59 (-6.39%)
Genetics in Medicine Open Study Demonstrates How Ambry Genetics’ ExomeReveal® RNA Testing Can Improve Diagnostic Clarity in Exome Testing Business Wire - Tue Jun 9, 5:00AM CDT

Research highlights how ExomeReveal RNA analysis resolves ambiguity around uncertain variants to enable more genetic disease diagnoses

TEM : 53.59 (-6.39%)
Tempus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference Business Wire - Fri Jun 5, 3:01PM CDT

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that it will participate in the Goldman Sachs 47th Annual Global Healthcare...

TEM : 53.59 (-6.39%)
Tempus Launches Open-Source Digital Pathology Consortium, Names Yale New Haven Health and Leading Cancer Center as Founding Members Business Wire - Wed Jun 3, 7:30AM CDT

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, Yale New Haven Hospital (YNHH) and Memorial Sloan Kettering Cancer Center (MSK) today announced...

TEM : 53.59 (-6.39%)
Tempus Announces the Upcoming Clinical Availability of Its First Whole-Genome Sequencing Assay, xH Business Wire - Mon Jun 1, 7:30AM CDT

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the upcoming clinical availability of xH , a next-generation...

TEM : 53.59 (-6.39%)
Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug Development Business Wire - Sun May 31, 7:30AM CDT

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of the next-generation of Lens, its pioneering agentic AI platform...

TEM : 53.59 (-6.39%)

Barchart Exclusives

This Dividend King With a 64-Year Streak Is Beating the Market Barchart - Thu Jul 16, 6:30PM CDT
This Dividend King continues to beat the market by pairing reliable income with consistent business growth. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.